Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients.
Matucci
A
A
Department of Internal Medicine, Section of Immunoallergology and Respiratory Diseases, University of Florence, Policlinico di Careggi Viale Morgagni 85, 50134 Florence, Italy. a.matucci@dmi.unifi.it
Parronchi
P
P
Vultaggio
A
A
Rossi
O
O
Brugnolo
F
F
Maggi
E
E
Romagnani
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000276:immunology*; D003429:Cross Reactions; D016861:Cyclooxygenase Inhibitors / Q000276:immunology*; D004342:Drug Hypersensitivity / Q000276:immunology*; D005260:Female; D006801:Humans; D007783:Lactones / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013450:Sulfones / Q000276:immunology*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib